The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19

被引:4
|
作者
Aljadeed, Rana [1 ]
机构
[1] King Saud Univ, Coll Pharm, Riyadh, Saudi Arabia
关键词
covid-19; SARS-Cov-2; coronavirus; hydroxychloroquine; chloroquine; DRUG; AZITHROMYCIN; INFECTION;
D O I
10.1177/0897190021997399
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
On March 11th, the World Health Organization (WHO) announced the unprecedented outbreak of "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) to be a pandemic. Thus far, COVID-19 has infected over 58,229,138 individuals and caused 1,382,106 deaths worldwide. This has led to the re-purposing of available drugs under "off-label" use-drugs such as hydroxychloroquine and chloroquine. Both drugs have since been evaluated for their ability to treat COVID-19. Here, we summarize recent evidence regarding the use of hydroxychloroquine and chloroquine in hospitalized patients with COVID-19. All data is current as of November 23, 2020.
引用
收藏
页码:971 / 978
页数:8
相关论文
共 50 条